×

ATMI and Finesse Solutions Sign Distribution Agreement for Turnkey Bioreactor Systems

company logo

DANBURY, Conn., April 16, 2013 (GLOBE NEWSWIRE) -- ATMI, Inc. (Nasdaq:ATMI), a global technology company and a leader in single-use process solutions, announced the signing of a distribution agreement with Finesse Solutions, Inc., a manufacturer of measurement and control solutions for life sciences process applications. Over the last two years, and after several collaborative projects, the relationship between the companies has gained in strategic importance.

This agreement will allow both companies to offer customers seamless support for single-use bioreactor systems enabled by the ATMI single-use Integrity® PadReactor system and Finesse SmartSystems. The solution combines the optimized mixing and gas transfer performance of the space-efficient PadReactor bioreactor with the industry's leading bioreactor control platform and single-use sensors, namely, state-of-the-art TruFluor sensors for pH and dissolved oxygen and TruTorr sensors for pressure. The integrated system couples the ATMI LifeScience Integrity PadReactor bioreactor with Finesse's G3-series SmartControllers and TruBio® 4.X DV software, which are pre-configured for controlling process parameters such as pH, dissolved oxygen, temperature, agitation, gas/liquid flow and auxiliary analog inputs/loops.

The integrated ATMI-Finesse bioreactor system can be purchased in a single transaction with follow-on application and technical support from both ATMI and Finesse. Under the terms of the agreement, Finesse will offer fully-integrated turnkey systems for upstream bioprocessing. Additionally, ATMI will provide all post-point-of-sale customer requirements for PadReactor hardware and disposables while Finesse will support and service the controller, sensors and software.

"Based on the DeltaV® control platform from Emerson, Finesse controllers allow users to scale their processes seamlessly from 1 Liter lab-scale R&D bioreactors into cGMP single-use process trains having volumes up to 2,000 Liters," stated Finesse CEO Barbara Paldus. "By integrating our measurement and control solutions with the PadReactor system, Finesse will be able to offer a superior solution to its customer base for the production of recombinant proteins or vaccines. The end results will include suspension cell configurations as well as the most effective and productive system for micro-carrier based processes in the industry."

Global Director of Business Development for ATMI LifeSciences, Jeffery Craig, added, "The PadReactor system is specifically designed to meet the needs of cell culturists and is perfectly suited to process development, clinical material supply and flexible GMP manufacturing. It has an innovative, cube-shaped bioreactor vessel which offers functionality that is comparable or better than classical stirred-tank bioreactors. It also includes a single-use bag integrating an internal low-shear mixing paddle and sparger system. It is considerable end-user value that all ATMI bags are made with our in-house produced TK8 film which is designed specifically for cell culture and bioprocess applications."

The PadReactor system is available in sizes ranging from 25 Liter to 1,200 Liter, and has been engineered to work in harmony with Finesse's cGMP-capable, highly configurable SmartSystems which features comprehensive functionality combined with easy process configuration and display.

For more information on the turnkey bioreactor system, please contact ATMI LifeSciences or Finesse representatives. For more information about ATMI products and services at INTERPHEX 2013, please visit www.atmi.com/Events/interphex-2013.aspx.

About ATMI

ATMI, Inc. provides specialty semiconductor materials, and safe, high-purity materials handling and delivery solutions designed to increase process efficiencies for the global semiconductor, flat panel, and life sciences industries. For more information, please visit www.atmi.com.

About ATMI LifeSciences

ATMI LifeSciences is an acknowledged technology leader in the field of single-use bioprocess systems and consumables for the pharmaceutical and biopharmaceutical industries. Its innovative, market-leading portfolio of custom-engineered, flexible packaging solutions, single-use storage systems, mixers and bioreactors is driving bioprocess efficiency and delivering value for biopharmaceutical companies around the world. For more information, please visit www.atmi-lifesciences.com.

ATMI, the ATMI logo, Integrity and PadReactor are trademarks or registered trademarks of ATMI, Inc., in the United States, other countries or both. All other names are trademarks of their respective companies.

About Finesse Solutions, Inc.

California-based Finesse Solutions, Inc., has established a proven record in providing turnkey, scalable solutions for single-use upstream bioprocessing. The Finesse product platform includes an extensive portfolio of novel disposable sensors, modular configure-to-order automation hardware, and intelligent software that can harmonize global bioprocess information and technology transfer. Finesse also offers a complete set of services including startup, commissioning, and validation for rapid and reliable deployment of single-use equipment into cGMP manufacturing applications. Visit www.finesse.com.

Finesse Solutions, the Finesse logo, SmartSystems, SmartControllers, TruBio, TruFluor and TruTorr are trademarks or registered trademarks of Finesse Solutions Inc., in the United States, other countries or both. All other names are trademarks of their respective companies.

Forward Looking Statements

Statements contained herein that relate to ATMI's future performance, including, without limitation, statements with respect to ATMI's anticipated results of operations or level of business for 2013 or any other future period, are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on current expectations only and are subject to certain risks, uncertainties, and assumptions, including, but not limited to, changes in semiconductor and life sciences industry growth (including, without limitation, wafer starts) or ATMI's markets; competition, problems, or delays developing, commercializing, and delivering new products; customer-driven pricing pressure; potential loss of key customers; problems or delays in integrating acquired operations and businesses; uncertainty in the credit and financial markets; ability to protect ATMI's proprietary technology; and other factors described in ATMI's Form 10-K for the year ended December 31, 2012 and other subsequent filings with the Securities and Exchange Commission. Such risks and uncertainties may cause actual results to differ materially from those expressed in our forward-looking statements. ATMI undertakes no obligation to update any forward-looking statements.

CONTACT: ATMI Contact: Troy Dewar Director of Investor Relations 203.207.9349 tdewar@atmi.com Media Contact: Beth Willers Impress Labs 415.846.9891 beth@impresslabs.com

Source:ATMI, Inc.